The genetic testing company has now raised $225m after Alphabet, Illumina and WuXi PharmaTech took part in a Fidelity-led round that valued it at $1.1bn.

US-based personal genetics analysis service 23andme raised $115m yesterday in a series E round backed by Google Ventures, internet and technology company Alphabet’s corporate venturing arm.

Fidelity Management & Research led the round, which also included genetic research firm Illumina and WuXi Healthcare Ventures, the strategic investment subsidiary of pharmaceutical company WuXi PharmaTech, as well as Casdin Capital, Xfund, New Enterprise Associates (NEA) and MPM Capital.

Founded in 2006, 23andme operates a service whereby customers can send a saliva sample…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?